Novel Tetrahydropyrido[3,4- d]pyrimidines as HPK1 Inhibitors for Treating Cancer, Inflammatory, and Autoimmune Diseases

Abstract

Provided herein are novel tetrahydropyrido[3,4-d]pyrimidines as HPK1 inhibitors, pharmaceutical compositions, use of such compounds in treating cancer, inflammatory, and autoimmune diseases, and processes for preparing such compounds.